|
|
||||||||
Review Article |
-Tocopheryl Succinate, the Most Effective Form of Vitamin E for Adjuvant Cancer Treatment: A Review
Center for Vitamins and Cancer Research, Department of Radiology, University of Colorado Health Sciences Center, Denver, Colorado
Address reprint requests to: Kedar N. Prasad, Ph.D., Campus Box C-278, UCHSC, 4200 E. 9th Ave. Denver, CO 80262. E-mail: Kedar.Prasad{at}UCHSC.edu
In 1982, it was established that alpha-tocopheryl succinate (
-TS) was the most effective form of vitamin E in comparison to
-tocopherol,
-tocopheryl acetate and
-tocopheryl nicotinate in inducing differentiation, inhibition of proliferation and apoptosis in cancer cells, depending upon its concentration. During the last two decades, several studies have confirmed this observation in rodent and human cancer cells in culture and in vivo (animal model). The most exciting aspect of this
-TS effect is that it does not affect the proliferation of most normal cells. In spite of several studies published on the anti-cancer properties of
-TS, the value of this form of vitamin E has not drawn significant attention from researchers and clinicians. Therefore, a critical review on the potential role of
-TS in the management of cancer is needed. In addition, such a review can also provide in-depth analysis of existing literature on this subject.
-TS treatment causes extensive alterations in gene expression; however, only some can be attributed to differentiation, inhibition of proliferation and apoptosis.
-TS also enhances the growth-inhibitory effect of ionizing radiation, hyperthermia, some chemotherapeutic agents and biological response modifiers on tumor cells, while protecting normal cells against some of their adverse effects. Thus,
-TS alone or in combination with dietary micronutrients can be useful as an adjunct to standard cancer therapy by increasing tumor response and possibly decreasing some of the toxicities to normal cells.
Key words:
-tocopheryl succinate, cancer, gene expressions, differentiation, growth inhibition, apoptosis
This article has been cited by other articles:
![]() |
X. Gu, X. Song, Y. Dong, H. Cai, E. Walters, R. Zhang, X. Pang, T. Xie, Y. Guo, R. Sridhar, et al. Vitamin E Succinate Induces Ceramide-Mediated Apoptosis in Head and Neck Squamous Cell Carcinoma In vitro and In vivo Clin. Cancer Res., March 15, 2008; 14(6): 1840 - 1848. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Zhong, B. Han, I. L. Tourkova, A. Lokshin, A. Rosenbloom, M. R. Shurin, and G. V. Shurin Low-Dose Paclitaxel Prior to Intratumoral Dendritic Cell Vaccine Modulates Intratumoral Cytokine Network and Lung Cancer Growth Clin. Cancer Res., September 15, 2007; 13(18): 5455 - 5462. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-W. Shiau, J.-W. Huang, D.-S. Wang, J.-R. Weng, C.-C. Yang, C.-H. Lin, C. Li, and C.-S. Chen {alpha}-Tocopheryl Succinate Induces Apoptosis in Prostate Cancer Cells in Part through Inhibition of Bcl-xL/Bcl-2 Function J. Biol. Chem., April 28, 2006; 281(17): 11819 - 11825. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Donapaty, S. Louis, E. Horvath, J. Kun, S. M. Sebti, and M. P. Malafa RRR-{alpha}-Tocopherol succinate down-regulates oncogenic Ras signaling. Mol. Cancer Ther., February 1, 2006; 5(2): 309 - 316. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Zu, L. Hawthorn, and C. Ip Up-regulation of c-Jun-NH2-kinase pathway contributes to the induction of mitochondria-mediated apoptosis by {alpha}-tocopheryl succinate in human prostate cancer cells Mol. Cancer Ther., January 1, 2005; 4(1): 43 - 50. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. N. Prasad Multiple Dietary Antioxidants Enhance the Efficacy of Standard and Experimental Cancer Therapies and Decrease Their Toxicity Integr Cancer Ther, December 1, 2004; 3(4): 310 - 322. [Abstract] [PDF] |
||||
![]() |
C. Borek Dietary Antioxidants and Human Cancer Integr Cancer Ther, December 1, 2004; 3(4): 333 - 341. [Abstract] [PDF] |
||||
![]() |
C. Borek Antioxidants and Radiation Therapy J. Nutr., November 1, 2004; 134(11): 3207S - 3209S. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |